-
Baird Goes Neutral On Johnson Controls: 'Our Prior Thesis Has Failed To Materialize'
Friday, January 5, 2018 - 5:48pm | 437Johnson Controls International plc (NYSE: JCI) received a Friday downgrade from Baird, with the firm saying the HVAC company is trading at fair value. The Analyst Baird Equity Research's Timothy Wojs downgraded Johnson Controls from Outperform to Neutral and decreased...
-
Could Under Armour Have Its Fundamentals On Track In Less Than A Year?
Tuesday, December 5, 2017 - 4:02pm | 806Despite Under Armour Inc (NYSE: UAA)'s catastrophic year, one analyst is maintaining a bullish stance on the company, projecting that long-term investors will be rewarded if they stay the course ahead of a sentiment shift that could come in less than a year. The Analyst...
-
What Wall Street Thinks Of The $69 Billion CVS-Aetna Deal
Monday, December 4, 2017 - 6:24pm | 1067Here we have it: the largest deal of 2017. CVS Health Corp (NYSE: CVS) confirmed Monday its agreement to acquire Aetna Inc (NYSE: AET) as a standalone business unit for about $207 per share. The parties intend to close the deal in the second half of 2018 to yield $750 million in near-term synergies...
-
Your End-Of-Year Guide To Apparel, Footwear, Fitness Stocks
Wednesday, November 29, 2017 - 9:19am | 708Baird Equity Research is encouraged by improving retail sales and is advocating for investors to maintain exposure to cold-weather brands and vendors — while steering clear of brick-and-mortar retailers. With colder year-over-year weather in the Midwest and Northeast over the holidays...
-
Micron Gets A Price Target Boost On An An Optimistic DRAM Outlook
Tuesday, November 28, 2017 - 11:24am | 389Micron Technology, Inc. (NASDAQ: MU) is one of 2017's hottest stocks, but some analysts see a path toward even more upside amid encouraging DRAM pricing trends. The Analyst Baird Equity Research's Tristan Gerra maintains an Outperform rating on Micron's stock with a price target...
-
Thor Industries Hammers Expectations With Strong Q1 Beat
Tuesday, November 28, 2017 - 10:29am | 423Thor Industries, Inc. (NYSE: THO) reported fiscal first quarter results Monday, posting a strong top- and bottom-line beat. The Analyst Baird Equity Research's Craig Kennison maintains an Outperform rating on Thor's stock with a price target boosted from $136 to $160. The...
-
Twilio Q3 Preview: 7 Recent Rating And Price Target Changes
Wednesday, November 8, 2017 - 2:35pm | 306Despite having reported four consecutive quarters of in-line or better earnings, Twilio Inc (NYSE: TWLO) traded down 3 percent Wednesday ahead of its third-quarter release. But Wall Street is notably optimistic on the name. Consensus reports a $39 average price target representing 29-percent upside...
-
Mobile Monetization Makes Its Mark In Activision's Q3 Beat
Friday, November 3, 2017 - 11:38am | 486Digital and mobile monetization played a big role in Activision Blizzard, Inc. (NASDAQ: ATVI)'s third quarter earnings beat, Baird Equity Research's Colin Sebastian said in a research report. The video game company reported a 17 percent year-over-year increase in its third quarter revenue...
-
As iPhone Outlook Is Tempered, So Too Baird's Himax Estimates
Friday, October 20, 2017 - 3:16pm | 383With concerns surrounding the iPhone 8, fear of anemic demand is spreading to ancillary component manufacturers. 3D sensing manufacturer Himax Technologies, Inc. (NASDAQ: HIMX) had its estimates reduced by Baird Equity Research as a result of a weaker-than-expected iPhone outlook for the rest of...
-
Athenahealth Q3 Just A Little Worse Than Expected, Things Could Get Better From Here
Friday, October 20, 2017 - 2:01pm | 237Baird Equity Research maintains an Outperform rating for athenahealth, Inc (NASDAQ: ATHN) after the company reported earnings Thursday after the market close. Analyst Michael Gillmor thinks the third-quarter report was just slightly worse than feared, but the risk-reward is still favorable. The...
-
Celgene's Pipeline In Question After GED Failure
Friday, October 20, 2017 - 11:44am | 353After announcing the termination of its mongerson program for Crohn’s disease, Celgene Corporation (NASDAQ: CELG) is looking more and more unwell. “While the loss of one of the company's most advanced and high-profile pipeline programs is, in and of itself, disappointing, we believe...
-
AMD Becomes 'Top Medium-Term Idea' At Baird
Monday, October 16, 2017 - 1:50pm | 301In the technology and semiconductor space, Baird Equity Research issued a few notable updates Monday. It raised its estimates, ratings and price targets for Diodes Incorporated (NASDAQ: DIOD) and ON Semiconductor Corp (NASDAQ: ON). The firm called Advanced Micro Devices, Inc. (NASDAQ: AMD) its top...
-
How The Experts Reacted To Tesla's Q3 Deliveries
Tuesday, October 3, 2017 - 3:41pm | 709Tesla Inc (NYSE: TSLA) falling short of its production goals in the third quarter has Wall Street analysts weighing in on the company's "production bottlenecks." In the third quarter, Tesla produced 260 Model 3 vehicles and delivered just 220, against its Aug. 2 forecast of over 1,500 units....
-
Patent Applications Hint At Tesla's Forthcoming Innovations
Friday, September 29, 2017 - 6:03pm | 449Elon Musk is spread pretty thin these days as he manages The Boring Company, SpaceX and Tesla Inc (NASDAQ: TSLA). In turn, Tesla’s spread pretty thin as it balances ventures in automotive manufacturing, solar energy and battery construction. As a Musk investor, it’s difficult to know...
-
Nike Sell-Side Roundup: Staying Bullish Is The Right Foot Forward
Wednesday, September 27, 2017 - 3:30pm | 495Despite its slight earnings beat, Nike Inc (NYSE: NKE) fell as much as 5 percent Wednesday after management guided for contracted gross margins and dampened sales growth. However, analysts professed justified bullishness. Here is what the sell-side had to say about Nike after its Tuesday quarterly...